NEUE · As filed with the SEC
NeueHealth income statement, by quarter
The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Income (Loss) · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|
| Revenue: | ||||
| Capitated revenue | 82,532 | 80,987 | — | 71,334 |
| Service revenue | 10,420 | 9,834 | — | 11,666 |
| ACO REACH revenue | 115,339 | 124,040 | 154,249† | 149,477 |
| Investment income | 791 | 926 | — | 456 |
| Total revenue | 209,082 | 215,787 | 232,638† | 232,933 |
| Operating expenses: | ||||
| Medical costs | 146,410 | 160,894 | 184,892† | 182,693 |
| Operating costs | 44,860 | 48,673 | 72,786† | 64,075 |
| Bad debt expense | — | — | 0† | 3 |
| Restructuring charges | — | — | 775† | 0 |
| Goodwill impairment | — | — | 0† | 0 |
| Depreciation and amortization | 3,555 | 3,559 | — | 3,504 |
| Intangible assets impairment | 0 | — | 0† | 0 |
| Total operating expenses | 194,825 | 213,126 | 262,055† | 250,275 |
| Operating income (loss) | 14,257 | 2,661 | (29,417)† | (17,342) |
| Interest expense | 6,878 | 6,637 | 6,248† | 5,413 |
| Warrant expense (income) | 562 | (2,649) | — | 459 |
| Gain on troubled debt restructuring | 0 | 0 | 0† | 0 |
| Income (Loss) from continuing operations before income taxes | 6,817 | (1,327) | (43,152)† | (23,214) |
| Income tax (benefit) expense | (21) | 111 | (672)† | 2,793 |
| Net income (loss) from continuing operations | 6,838 | (1,438) | (42,480)† | (26,007) |
| Loss from discontinued operations, net of tax | (8,386) | (9,410) | 45,003† | (14,358) |
| Net Loss | (1,548) | (10,848) | 2,523† | (40,365) |
| Net income from continuing operations attributable to noncontrolling interests | (8,507) | (891) | (5,245)† | (17,049) |
| Redeemable Series A preferred stock | (10,981) | (10,729) | — | (10,667) |
| Redeemable Series B preferred stock | (2,465) | (2,407) | — | (2,394) |
| Net loss attributable to NeueHealth, Inc. common shareholders | (23,501) | (24,875) | (15,947)† | (70,475) |
| Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders | ||||
| Continuing operations, basic (in dollars per share) | (1.68) | (1.80) | — | (6.78) |
| Continuing operations, diluted (in dollars per share) | (1.68) | (1.80) | — | (6.78) |
| Discontinued operations, basic (in dollars per share) | (0.94) | (1.10) | — | (1.73) |
| Discontinued operations, diluted (in dollars per share) | (0.94) | (1.10) | — | (1.73) |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | (2.62) | (2.90) | — | (8.51) |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | (2.62) | (2.90) | — | (8.51) |
| Basic weighted-average common shares outstanding (in shares) | 8,978 | 8,570 | — | 8,282 |
| Diluted weighted-average common shares outstanding (in shares) | 8,978 | 8,570 | — | 8,282 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.